HOUSTON -- Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer. The study, led by The ...
from Google Alert - health https://ift.tt/2lg9kEK
via IFTTT
0 comments:
Post a Comment